Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030794 (pelvic pain)
 4,056 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Extracontraceptive benefits are common to all oral contraceptives; however, some benefits are more pronounced with particular associations. To improve acne, hirsutism and premenstrual symptoms, for example, oral contraceptives containing drospirenone are more effective. This interesting progestin has marked antiandrogenic and antimineralcorticoid activity. EE/DRSP 24+4 (24 tablets containing hormones plus 4 containing placebo) features an innovative dosing regimen. Shortening of the hormone-free period augments the inhibition of ovulation and reduces fluctuations in hormones, with beneficial effects on withdrawal symptoms, including headache, breast tenderness, mood swings and pelvic pain. Use of EE/DRSP 24+4 for 3 days longer than conventional oral contraceptives also has extracontraceptive benefits, as demonstrated in clinical trials which have evaluated improvement in premenstrual symptoms, acne and hirsutism.
 ...
PMID:[Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen]. 2059 50

This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD), in women with endometriosis-associated pain (n = 252). All treatments induced minimal mean changes from baseline in BMD at week 24 (elagolix 150 mg: -0.11%/-0.47%, elagolix 75 mg: -1.29%/-1.2%, and DMPA-SC: 0.99%/-1.29% in the spine and total hip, respectively), with similar or less changes at week 48 (posttreatment). Elagolix was associated with improvements in endometriosis-associated pain, assessed with composite pelvic signs and symptoms score (CPSSS) and visual analogue scale, including statistical noninferiority to DMPA-SC in dysmenorrhea and nonmenstrual pelvic pain components of the CPSSS. The most common adverse events (AEs) in elagolix groups were headache, nausea, and nasopharyngitis, whereas the most common AEs in the DMPA-SC group were headache, nausea, upper respiratory tract infection, and mood swings. This study showed that similar to DMPA-SC, elagolix treatment had minimal impact on BMD over a 24-week period and demonstrated similar efficacy on endometriosis-associated pain.
...
PMID:Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. 2524 68